A single sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve

被引:45
作者
GhazalAswad, S [1 ]
Calvert, AH [1 ]
Newell, DR [1 ]
机构
[1] UNIV NEWCASTLE UPON TYNE,SCH MED,CANC RES UNIT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND
关键词
carboplatin; pharmacokinetics; limited-sampling strategy; AUC estimation; AUC; single-sample assay;
D O I
10.1007/s002800050408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to develop and validate a simple and rapid method for the estimation of the area under the free carboplatin plasma concentration versus time curve (AUC). The relationship between the carboplatin AUC and the total plasma platinum (Pt) concentration 24 h after treatment was studied using data from 49 patients treated with 20-1600 mg/m(2) carboplatin as a 60-100 min infusion (median 60 min). The relationship was confirmed by the in vitro incubation of carboplatin in human plasma and prospectively validated in 13 ovarian cancer patients. Free carboplatin was separated by ultrafiltration (MW cut off 30,000), and free and total Pt measured by atomic absorption spectrophotometry. There was a linear relationship in vivo between the 24 h (median 24.4; range 16.3-27.3 h) total plasma Pt concentration (mu M) and free carboplatin AUC (mg/ml.min): AUC=(24 h Pt+0.3)/0.82 (r(2)=0.93, AUC median 5.8 (0.13-28)mg/ml.min, 24 h Pt median 4.4 (0.1-23) mu M). A similar relationship was observed in vitro [AUC=(24 h Pt+0.1)/0.93 (r(2)=0.98, AUC median 7.9 (2.0-17) mg/ml.min, 24 h Pt median 7.1 (1.8-15) mu M)]. The relationship derived from the in vivo data gave an unbiased and reasonably accurate estimate of the measured carboplatin AUC in 13 patients (AUC=5.1-8.7 mg/ml.min, GFR=59-129 ml/min, infusion time 30-45 min, 24 h sampling time 22.9-24.5 h), giving a percentage mean error of -4.2% and root mean squared percentage error of 11.5%. These results show that the analysis of a single blood sample taken 24 h after carboplatin administration can be used to produce an unbiased and reasonably accurate measure of the free carboplatin AUC. Unlike published limited sampling strategies, this method is not complicated by the need to accurately control the duration of the carboplatin infusion or the time at which the sample is taken.
引用
收藏
页码:429 / 434
页数:6
相关论文
共 13 条
[1]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[2]  
EGORIN MJ, 1984, CANCER RES, V44, P5432
[3]  
FOURNIER C, 1988, CANCER CHEMOTH PHARM, V21, P75
[4]  
HARLAND SJ, 1984, CANCER RES, V44, P1693
[5]   CARBOPLATIN DOSE IN COMBINATION CHEMOTHERAPY FOR TESTICULAR CANCER [J].
HARLAND, SJ ;
GUMBRELL, LA ;
HORWICH, A .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (06) :691-695
[6]   EFFECTIVENESS OF CARBOPLATIN, ETOPOSIDE, AND BLEOMYCIN COMBINATION CHEMOTHERAPY IN GOOD-PROGNOSIS METASTATIC TESTICULAR NONSEMINOMATOUS GERM-CELL TUMORS [J].
HORWICH, A ;
DEARNALEY, DP ;
NICHOLLS, J ;
JAY, G ;
MASON, M ;
HARLAND, S ;
PECKHAM, MJ ;
HENDRY, WF .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :62-69
[7]   RELATIONSHIPS BETWEEN CARBOPLATIN EXPOSURE AND TUMOR RESPONSE AND TOXICITY IN PATIENTS WITH OVARIAN-CANCER [J].
JODRELL, DI ;
EGORIN, MJ ;
CANETTA, RM ;
LANGENBERG, P ;
GOLDBLOOM, EP ;
BURROUGHS, JN ;
GOODLOW, JL ;
TAN, S ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :520-528
[8]   CARBOPLATIN AND ETOPOSIDE PHARMACOKINETICS IN PATIENTS WITH TESTICULAR TERATOMA [J].
NEWELL, DR ;
EELES, RA ;
GUMBRELL, LA ;
BOXALL, FE ;
HORWICH, A ;
CALVERT, AH .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (06) :367-372
[9]   SOME SUGGESTIONS FOR MEASURING PREDICTIVE PERFORMANCE [J].
SHEINER, LB ;
BEAL, SL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (04) :503-512
[10]   A LIMITED SAMPLING METHOD FOR ESTIMATION OF THE CARBOPLATIN AREA UNDER THE CURVE [J].
SORENSEN, BT ;
STROMGREN, A ;
JAKOBSEN, P ;
JAKOBSEN, A .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 31 (04) :324-327